The early results showed that 15 of 41 evaluable patients had objective responses and 32 had stable disease with the ...

Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to ...

BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated ...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Immuneering Corporation has reported updated Phase 2a data showing atebimetinib plus modified gemcitabine/nab-paclitaxel ...

Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...

Researchers examined the long-term natural history of branch-duct intraductal papillary mucinous neoplasms and sought to identify clinical and radiologic factors linked to developing pancreatic cancer ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

Immuneering shares traded lower after new pancreatic cancer trial data showed improved survival, manageable safety, and key ...

The PAAG regimen significantly improved PFS and response rates in metastatic pancreatic cancer compared to chemotherapy alone ...

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...